James P. Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA.
Cell Stem Cell. 2012 Sep 7;11(3):359-72. doi: 10.1016/j.stem.2012.05.024. Epub 2012 Aug 2.
Leukemia stem cells (LSCs) represent a biologically distinct subpopulation of myeloid leukemias, with reduced cell cycle activity and increased resistance to therapeutic challenge. To better characterize key properties of LSCs, we employed a strategy based on identification of genes synergistically dysregulated by cooperating oncogenes. We hypothesized that such genes, termed "cooperation response genes" (CRGs), would represent regulators of LSC growth and survival. Using both a primary mouse model and human leukemia specimens, we show that CRGs comprise genes previously undescribed in leukemia pathogenesis in which multiple pathways modulate the biology of LSCs. In addition, our findings demonstrate that the CRG expression profile can be used as a drug discovery tool for identification of compounds that selectively target the LSC population. We conclude that CRG-based analyses provide a powerful means to characterize the basic biology of LSCs as well as to identify improved methods for therapeutic targeting.
白血病干细胞(LSCs)代表了髓系白血病中具有生物学差异的亚群,其细胞周期活性降低,对治疗挑战的抵抗力增强。为了更好地表征 LSCs 的关键特性,我们采用了一种基于鉴定协同失调的致癌基因的策略。我们假设,这样的基因,称为“合作反应基因”(CRGs),将代表 LSC 生长和存活的调节剂。我们使用原发性小鼠模型和人类白血病标本表明,CRGs 包括在白血病发病机制中以前未描述的基因,其中多条途径调节 LSCs 的生物学。此外,我们的研究结果表明,CRG 表达谱可用作药物发现工具,以鉴定选择性靶向 LSC 群体的化合物。我们得出结论,基于 CRG 的分析为表征 LSCs 的基础生物学以及识别用于治疗靶向的改进方法提供了有力手段。